Governments have consistently approached change as a coordinated exercise, bundling multiple elements into single negotiations rather than adjusting one lever at a time. This pattern has shaped outcomes across pricing, pharmacy agreements, and the evolution of both off-patent and innovative medicine sectors, and it continues to define how the next phase of reform is likely to unfold.
Those who recognise and respond to the reality will be better positioned to shape reforms
March 31, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
LENZ and Arrotex partner to bring once daily presbyopia treatment to Australia and New Zealand
June 25, 2026 - - Latest News -
New report highlights the risk of inaction on diabetes technology
June 25, 2026 - - Latest News -
Key report findings - 'Cost of Inaction - Australian voices on equitable access to diabetes technology'
June 25, 2026 - - BioPharma -
New Zealand last among peers for publicly funded modern medicines
June 25, 2026 - - Latest News -
A 'Stronger PBS' makes way for 'We are now in a fight to save the PBS'
June 25, 2026 - - Latest News -
Early real world data shows improvement in treatment resistant depression
June 24, 2026 - - Latest News -
FDA backs AFT’s injectable iron into Phase 3 study as company targets global scale
June 24, 2026 - - Latest News


